Oculis Holding AG

Healthcare · Biotechnology · Switzerland

Last price 8.26 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 509.91M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da...